Welcome To Campus Sanofi Singapore

In this issue, we feature three studies that provide insights into disease modification in atopic dermatitis, examining microbiome restoration, long-term infection outcomes in real-world practice, and clinical responses in erythrodermic presentations.

Missed this webinar? You can now watch the recording of the webinar to learn about the role of biologics in severe asthma and COPD through real-world clinical cases presented by a panel of expert clinicians.

Curated evidence on atopic dermatitis, organised around the four disease-modification pillars — starting with new data on skin-barrier restoration in children.

Curated June evidence on atopic dermatitis, organised around the four disease-modification pillars — starting with new data on skin-barrier restoration in children

The United in RARE: Advancing LSDs Care Across Asia meeting was held on 22–23 November 2025 in Bangkok, Thailand, bringing together experts from across Asia to share insights, clinical experiences, and best practices in the diagnosis and management of Gaucher disease and Acid Sphingomyelinase Deficiency (ASMD), with a focus on improving patient identification, treatment access, and long-term outcomes.

Explore ATS 2026 key sessions on dupilumab, COPD biologics, FeNO biomarkers, and asthma remission. Real-world evidence for HCPs

SCORE-AD Calculator & Atopic Dermatitis Assessment Tools for Healthcare Professionals. Access validated severity scales including SCORAD, EASI, vIGA-AD, DLQI, and POEM to evaluate disease severity, patient outcomes, and quality of life in one platform.